Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3181 - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Basic Science

Tumour Site

Presenters

Francesca Zannier

Citation

Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238

Authors

F. Zannier, S. Di Bella, S. Della Torre, P. Candido, M. Pelliccione, A. Della Vedova, C. Cozzi, R. Bollina

Author affiliations

  • Medical Oncology, Azienda Ospedaliera G. Salvini, 20017 - Rho/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3181

Background

Oral pain, odynophagia and dysphagia, weight loss, dehydration, systemic infection, feeding support and hospitalization should be mentioned as the main determinated effect of oral mucositis (OM); this toxicity is often linked to chemo- or chemoradiotherapy. Oral Mucositis can reduce patients’compliance to cancer treatment and decreased their quality of life; it could be also reduce survival caused by discontinuation or dose reduction of anti-neoplasm therapy. The purpose of this study is to evaluate the impact of the three different products on OM outcomes of patients who received radio and chemotherapy in solid cancer.

Methods

From March to June 2018, 60 patients (pts) were randomized by Medical Oncology Unit of Rho - Milan. The pts were divided in 3 arms, belanced for tumor site and treatment, to receive the following medical devices: Gelx (oral spray), Episil (oral solution) and Gelclair (oral gel). Primary aim of the study was evaluation of OM onset, severity, reduction or remission and pain relief with the three devices in study. We analysed data with forms compiled by pts in 2 different steps: T0 (baseline) and follow-up (after 16 w); the clinicians evaluated OM grade in 2 steps: after 4 w and after 8 w. The pts’safety profile form included 10 items concerning difficulty of speaking, feeding, drinking and change of taste.

Results

The data analysis showed a significant difference among the 3 Groups. OM grade of Group 2 after 4 weeks is higher if compared with Group 1 and Group 3 After 4 weeks two cases of grade 4 mucositis has been achieved in Group 2, none in Group 1 and Group 3. Group GELX (Zinco gluconate included) demonstrated an overall better efficacy, in every analyzed safety profile items.

Conclusions

Even if prevention and treatment of OM are not yet clearly defined and recognized in the clinical practice, the study shows how the correct use of anti- mucositis product (accompanied by an appropriate hygienic and dietetic regimen) seems to be effective in the prevention of this pathology, which is the most frequent side effects on patients undergoing chemotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.